FindTrial
Sign In

Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Status
APPROVED_FOR_MARKETING
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT06132191
Enrollment
Unknown
Registered
2023-11-15
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Basal Cell Carcinoma (BCC), Cutaneous Squamous Cell Carcinoma (CSCC), Non-Small Cell Lung Cancer (NSCLC)

Brief summary

Provide expanded access of cemiplimab in patients with solid tumors

Detailed description

Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications. Availability will depend on location.

Interventions

DRUGCemiplimab

Sponsors

Regeneron Pharmaceuticals
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026